Adaptive Fluorodeoxyglucose-Positron Emission Tomography Based Chemotherapy Selection for Metastatic Non-small Cell Lung Cancer.

Eaton, Keith D; Romine, Perrin E; Martins, Renato G; Leblond, Antoine; Carr, Laurie L; Vesselle, Hubert J

Eaton, Keith D; Romine, Perrin E; Martins, Renato G; Leblond, Antoine; Carr, Laurie L; Vesselle, Hubert J.

Afiliación

Eaton KD; Medical Oncology, University of Washington, Seattle, USA.
Romine PE; Medical Oncology, University of Washington, Seattle, USA.
Martins RG; Medical Oncology, University of Washington, Seattle, USA.
Leblond A; Nuclear Medicine, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, CAN.
Carr LL; Oncology, National Jewish Hospital, Denver, USA.
Vesselle HJ; Nuclear Medicine, Fred Hutchinson Cancer Research Center, Seattle, USA.

Cureus ; 13(10): e18804, 2021 Oct.

Article en En | MEDLINE | ID: mdl-34796077

Palabras clave

(18f)-fdg pet; adaptive clinical trial; cisplatin; metastatic; non-small cell lung cancer; paclitaxel

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Cureus Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google